Biostatistics Weekly Seminar

Design of current and future COVID-19 vaccine efficacy trials

Holly Janes, PhD
Fred Hutchinson Cancer Research Center

Rapid development and deployment of safe and effective COVID-19 vaccines for the global population is a public health imperative. We will overview the key statistical design elements of the first-generation US-government-funded vaccine efficacy trials, including the rationale and choice of endpoints, success criteria, triggers for analysis, and design adaptations following early evidence of efficacy. The implications of the emerging results for second-generation trials to evaluate additional vaccine candidates and to complete the profile of existing vaccines will be discussed.

Zoom (Link to Follow)
24 March 2021

Speaker Itinerary

Topic revision: r2 - 18 Mar 2021, AndrewSpieker

This site is powered by FoswikiCopyright © 2013-2022 by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Vanderbilt Biostatistics Wiki? Send feedback